Creating mRNA vaccines to boost antibody responses against HIV
Project 1 - Development of mRNA Immunogens for Protective Antibody Induction
This study is testing a new type of vaccine using mRNA technology to help your body fight HIV better by making stronger antibodies, which could lead to improved protection and lower chances of spreading the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10547802 on NIH RePORTER |
What this research studies
This research focuses on developing innovative mRNA immunogens aimed at enhancing the body's immune response to HIV. By utilizing mRNA technology, the project seeks to induce the production of protective antibodies that can effectively target and neutralize the virus. The approach involves designing multivalent mRNA vaccines that encode for various HIV antigens, which are expected to improve the efficacy of existing vaccine trials. Patients may benefit from this research as it aims to provide a more effective vaccine strategy against HIV, potentially leading to better protection and reduced transmission rates.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk of HIV infection or those who are currently unvaccinated against HIV.
Not a fit: Patients who are already HIV-positive or those who have previously received effective HIV vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly reduce the risk of HIV transmission.
How similar studies have performed: Previous vaccine trials have shown some success in using similar approaches, particularly in non-human primates, but this specific mRNA strategy is relatively novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Haynes, Barton F. — Duke University
- Study coordinator: Haynes, Barton F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.